Drugs / DA-2811-C
last change Nov 2025 re-read 2 minutes ago

DA-2811-C

Developed for
type 2 diabetes mellitus
Investigated by
Dong-A ST Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07239440 Nov 2025 → Dec 2026 expected type 2 diabetes mellitus Dong-A ST Co., Ltd. Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as DA-2811-C ClinicalTrials.gov intervention name — accepted as the source's own label NCT07239440
Route Oral “DA-2811-C + DA-2811-R1, orally, once daily” NCT07239440